Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mirabegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.82 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirabegron SCHEMBL904789 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL904788 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1405678 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993771 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL15993769 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL1509286 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| Mirabegron SCHEMBL16611070 | 0.97 | ADRB3 (0.94) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609366 | 0.90 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL16609248 | 0.90 | ADRB3 (0.81) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 | |
| SCHEMBL11914560 | 0.88 | ADRB3 (0.78) | ADRB3ADRB1ADRB2CYP2D6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10149837-B2 | Selective agonists of beta-adrenergic type 3 receptors (BAR3) and use thereof | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2018-12-11 | — | — | US | claimed |
| EP-3197449-B1 | SELECTIVE AGONISTS OF BETA-ADRENERGIC TYPE 3 RECEPTORS (BAR3) FOR THE TREATMENT OF NEPHROGENIC DIABETES INSIPIDUS | UNIV DEGLI STUDI DI BARI (IT) | 2018-11-21 | — | — | EP | claimed |
| EP-3177589-B1 | METHOD FOR THE SYNTHESIS OF MIRABEGRON AND ITS DERIVATIVES | INTERQUIM SA (ES) | 2018-06-20 | — | — | EP | claimed |
| US-9815771-B2 | Method for the synthesis of mirabegron and its derivatives | INTERQUIM, S.A. (ES) | 2017-11-14 | — | — | US | claimed |
| US-20170296516-A1 | SELECTIVE AGONISTS OF BETA-ADRENERGIC TYPE 3 RECEPTORS (BAR3) AND USE THEREOF | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2017-10-19 | — | — | US | claimed |
| US-8772315-B2 | Pharmaceutical composition for treating overactive bladder | ASTELLAS PHARMA INC. (JP) | 2014-07-08 | — | — | US | claimed |
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | claimed |
| EP-2298752-B1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC (JP) | 2013-03-27 | — | — | EP | claimed |
| EP-2216021-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC (JP) | 2012-10-17 | — | — | EP | claimed |
| US-7982049-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide and a carrier; diabetes, anti-obesity and anti-hyperlipemia | ASTELLAS PHARMA INC. (JP) | 2011-07-19 | — | — | US | claimed |
| EP-2298752-A1 | Alpha-form or beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | claimed |
| US-20100261770-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING LOWER URINARY TRACT SYMPTOMS | ASTELLAS PHARMA INC. (JP) | 2010-10-14 | — | — | US | claimed |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | ASTELLAS PHARMA INC. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2223690-A1 | PHARMACEUTICAL COMPOSITION FOR AMELIORATING LOWER URINARY TRACT SYMPTOM | Astellas Pharma Inc. (JP) | 2010-09-01 | — | — | EP | claimed |
| EP-2216021-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | claimed |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. | 2008-09-04 | — | — | US | claimed |
| EP-1932838-A2 | Beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | claimed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | claimed |
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | claimed |
| EP-1440969-A1 | ALPHA-FORM OR BETA-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-07-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB3 635/4885ADRB1 223/4885ADRB2 329/4885 |
| US-20130150402-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | ADRB3 27/4885ADRB1 43/4885ADRB2 17/4885 |
| US-20100240697-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OVERACTIVE BLADDER | BPHL, PDE12, UROD | ADRB3 23/4885ADRB1 36/4885ADRB2 17/4885 |
| US-20100261770-A1 | PHARMACEUTICAL COMPOSITION FOR IMPROVING LOWER URINARY TRACT SYMPTOMS | BPHL, REN, PRSS2 | ADRB3 326/4885ADRB1 286/4885ADRB2 193/4885 |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | ADRB3 760/4885ADRB1 249/4885ADRB2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.